Diagnostic Value of 68Ga-DOTATATE PET/CT in Liver Metastases of Neuroendocrine Tumours of Unknown Origin

被引：12

作者：

Tan T.H. ^{[1
]}

Lee B.N. ^{[1
]}

Hassan S.Z.A. ^{[1
]}

机构：

[1] Nuclear Medicine Department, Hospital Putrajaya, 62250 Putrajaya, Wilayah Persekutuan

来源：

Nuclear Medicine and Molecular Imaging | 2014年 / 48卷 / 3期

关键词：

Liver metastases; Neuroendocrine tumour; Unknown primary;

D O I：

10.1007/s13139-013-0258-9

中图分类号：

学科分类号：

摘要：

Purpose: In neuroendocrine liver metastases of unknown primary, a multimodality approach is usually adopted and consists of transabdominal ultrasound, endoscopic ultrasound (EUS), computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine techniques, endoscopy and exploratory surgery. The purpose of the study is to evaluate the diagnostic value of 68Ga-DOTATATE positron emission tomography (PET)/CT as part of a multimodality approach in neuroendocrine liver metastases of unknown primary. Materials and Methods: Six patients (M:F = 5:1, age range 28-56 years) with immunohistochemically proven neuroendocrine liver metastases but inconclusive initial CT work-up were retrospectively analysed. Clinical finding, histopathology, comparative imaging and follow-up were used to validate the results when ethically justified. Results: 68Ga-DOTATATE PET/CT identified the primary tumour in five out of six (83.3 %) patients: pancreas (n = 4) and stomach (n = 1). Out of three patients with indeterminate primary on initial CT, two patients were confirmed by 68Ga-DOTATATE PET/CT. Absence of uptake in indeterminate primary of one patient was later confirmed negative by histopathology. In another three patients with undetected primary on initial CT, primary site was demonstrated in all patients with unsuspected metastases in two patients on 68Ga-DOTATATE PET/ CT. No further work-up was done to confirm the primary in patients with distant metastases. Change of management was observed in three out of six (50 %) patients. Conclusion: Our small study indicates that 68Ga-DOTATATE PET/CT is a promising diagnostic option in the multimodality approach to neuroendocrine liver metastases of unknown primary origin. © 2013 Korean Society of Nuclear Medicine.

引用

页码：212 / 215

页数：3

共 27 条

[1]

Lawrence B., Gustafsson B.I., Chan A., Svejda B., Kidd M., Modlin I.M., The epidemiology of gastroenteropancreatic neuroendocrine tumors, Endocrinol Metab Clin North Am., 40, pp. 1-18, (2011)

[2]

Cerwenka H., Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search, World J Gastroenterol, 18, pp. 1009-1014, (2012)

[3]

Wang S.C., Parekh J.R., Zuraek M.B., Venook A.P., Bergsland E.K., Warren R.S., Et al., Identification of unknown primary tumors in patients with neuroendocrine liver metastases, Arch Surg, 145, pp. 276-280, (2010)

[4]

Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M., Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival, Ann Oncol, 19, pp. 1727-1733, (2008)

[5]

Falconi M., Plockinger U., Kwekkeboom D.J., Manfredi R., Korner M., Kvols L., Et al., Well-differentiated pancreatic nonfunctioning tumors/carcinoma, Neuroendocrinology, 84, pp. 196-211, (2006)

[6]

Ron B., Srirajaskanthan R., Ramage J.K., A multimodal approach to the management of neuroendocrine tumour liver metastases, Int J Hepatol, 2012, (2012)

[7]

Ambrosini V., Campana D., Tomassetti P., Grassetto G., Rubello D., Fanti S., PET/CT with <sup>68</sup>Gallium-DOTA-peptides in NET: an overview, Eur J Radiol, 80, (2011)

[8]

Bushnell D.L., Baum R.P., Standard imaging techniques for neuroendocrine tumors, Endocrinol Metab Clin North Am., 40, pp. 153-162, (2011)

[9]

Hofman M.S., Hicks R.J., Changing paradigms with molecular imaging of neuroendocrine tumors, Discov Med., 14, pp. 71-81, (2012)

[10]

Maecke H.R., Reubi J.C., Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment, J Nucl Med, 52, pp. 841-844, (2011)

← 1 2 3 →